ArticleTranslational cancer research2025
Clinical significance of CD155 expression and correlation with immune cell infiltration in triple-negative breast cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Revisiting the Prognostic Significance of CD155 in Invasive Breast Carcinoma.Iranian journal of pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As a newly focused immune checkpoint protein in cancers, CD155 is a potential target in immunotherapy. Tumor microenvironment (TME) as a crucial regulatory factor in immunotherapy, also plays a significant role in the development and progression of triple-negative breast cancer (TNBC). This study aims to further clarify the relationship between the expression of CD155 and TME in TNBC. Methods: We conducted a retrospective analysis of 182 patients with TNBC who underwent surgical treatment at The First Affiliated Hospital of Bengbu Medical University between January 2014 and December 2018. CD155, stromal tumor-infiltrating lymphocytes (sTILs), CD4, CD8, and CD163 expression levels in TNBC specimens were assessed by immunohistochemistry. We analyzed the expression of CD155, the degree of sTIL infiltration, the profiles of immune cell subsets, and their associations with clinicopathological characteristics and survival outcomes. At the same time, the relationship between CD155 expression, TNBC progression, and immune cell infiltration in the TME was evaluated using both the clinical samples and public datasets. Results: Among the 182 TNBC patients, 131 (72.0%) were CD155 high expression, and 51 (28.0%) were CD155 low expression. CD155 expression was positively correlated with tumor diameter, lymph node metastasis, and Ki-67 status (all P<0.05). There were 112 patients (61.5%) with sTILs low infiltration and 70 patients (38.5%) with sTILs high infiltration. One hundred and twelve (61.5%) were identified with sTIL slow infiltration and 70 (38.5%) with sTILs high infiltration, sTILs were negatively correlated with lymph node metastasis ( Conclusions: Overexpression of CD155 may contribute to the formation of the immunosuppressive TME mediated by M2 macrophages. CD155 overexpression introduced a worse relapse-free survival and OS and might be a potential immunotherapy target in TNBC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.